Artelo Biosciences Stock Current Liabilities
| ARTL Stock | USD 12.37 0.10 0.81% |
Fundamental analysis of Artelo Biosciences allows traders to better anticipate movements in Artelo Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Current Liabilities is expected to rise to about 1.9 M this year, although the value of Non Current Liabilities Total will most likely fall to about 65.5 K. Artelo | Current Liabilities | Build AI portfolio with Artelo Stock |
Artelo Biosciences Company Current Liabilities Analysis
Artelo Biosciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Artelo Biosciences Current Liabilities | 23.67 M |
Most of Artelo Biosciences' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Artelo Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Artelo Biosciences is extremely important. It helps to project a fair market value of Artelo Stock properly, considering its historical fundamentals such as Current Liabilities. Since Artelo Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artelo Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artelo Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Artelo Current Liabilities Historical Pattern
Today, most investors in Artelo Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Artelo Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Artelo Biosciences current liabilities as a starting point in their analysis.
Artelo Biosciences Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Artelo Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
In accordance with the recently published financial statements, Artelo Biosciences has a Current Liabilities of 23.67 M. This is 98.65% lower than that of the Pharmaceuticals sector and 95.64% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.7% higher than that of the company.
Artelo Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in current liabilities category among its peers.
Artelo Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Artelo Biosciences from analyzing Artelo Biosciences' financial statements. These drivers represent accounts that assess Artelo Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Artelo Biosciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 4.2M | 3.6M | 17.0M | 8.2M | 7.4M | 4.8M | |
| Enterprise Value | (212.0K) | 1.4M | 10.5M | 1.4M | 1.2M | 1.2M |
Artelo Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Artelo Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Artelo Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Artelo Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 9.11 M | ||||
| Shares Outstanding | 700.37 K | ||||
| Shares Owned By Insiders | 0.63 % | ||||
| Shares Owned By Institutions | 2.04 % | ||||
| Number Of Shares Shorted | 30.59 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 14.96 X | ||||
| EBITDA | (7.44 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | 1.19 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (17.94) X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 8.59 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 4.7 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Artelo Biosciences Piotroski F Score and Artelo Biosciences Altman Z Score analysis. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.